Physician profile
Mark J Paradela
NPI 1437131596
$3,616.87
in general payments reported to CMS, 2019-2025
36 companies · $534 in 2025
The $534 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $535 · 2020: $407 · 2021: $652 · 2022: $437 · 2023: $479 · 2024: $574 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,586.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $404.83 | 2019-2024 | Veozah |
| Astrazeneca Pharmaceuticals LP | $298.90 | 2019-2025 | Breztri, Farxiga |
| Sanofi-Aventis U.S. LLC | $253.48 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $245.59 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $243.13 | 2019-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $241.70 | 2019-2023 | Trelegy Ellipta |
| Amgen INC. | $237.67 | 2020-2025 | Evenity, Krystexxa, Prolia |
| Lilly USA, LLC | $223.31 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $175.71 | 2020-2025 | |
| Novo Nordisk INC | $147.62 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $122.05 | 2020-2025 | |
| Sunovion Pharmaceuticals INC. | $115.82 | 2019-2022 | |
| Abbott Laboratories | $107.99 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Allergan, INC. | $86.19 | 2019 | |
| Dexcom, INC. | $63.22 | 2024-2025 | Dexcom G6 Transmitter |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Paradela listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.